Screening High-Risk Groups and the General Population for SARS-CoV-2 Nucleic Acids in a Mobile Biosafety Laboratory.
SARS-CoV-2
bio-protection
mobile biosafety laboratory
nucleic acid
real-time PCR
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
06
2021
accepted:
09
07
2021
entrez:
6
9
2021
pubmed:
7
9
2021
medline:
9
9
2021
Statut:
epublish
Résumé
The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) pandemic has challenged public health systems worldwide. Therefore, large-scale testing capacity is extremely important diagnosis and exclusion diagnosis. However, fixed laboratories are limited or far away from remote areas. Fortunately, MBS-Lab is characterized by high mobility and rapid on-site detection of SARS-CoV-2 nucleic acid. MBS-Lab was first used in northern Australia during a melioidosis outbreak in 1997. The MBS-Lab and a well-trained diagnostic team were dispatched to Dongchang District, Tonghua City, Jilin Province, China to assist the SARS-CoV-2 virus screening and diagnosis on January 17, 2021. Altogether, 93,952 oropharyngeal swabs samples were collected and tested among the high-risk groups and the general population in Dongchang District. Two single samples were identified as positive in the second turn screening. In the second turn screening, 3 mixed samples (10 in 1) were identified as positive; 10 mixed samples were identified as positive in the third turn screening. By resampling again, one and four cases were identified as positive, respectively. The positive cases were properly isolated and treated in hospital and avoided to visit family members, friends, colleagues and any other persons. Through this way of large-scale screening, human-human spread of SARS-CoV-2 can be effectively avoided. In addition, all staff members strictly executed multiple safety precautions and reduce exposure risks. In the end, none of the staffs was infected with SARS-CoV-2 virus or other pathogens. As an emergency facility for infectious disease control, the MBS-Lab satisfies the requirements of ports and other remote areas far from fixed laboratories and supplements the capabilities of fixed laboratories.
Identifiants
pubmed: 34485233
doi: 10.3389/fpubh.2021.708476
pmc: PMC8414879
doi:
Substances chimiques
Nucleic Acids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
708476Informations de copyright
Copyright © 2021 Guo, Li, Song, Xu and Huang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Infect Genet Evol. 2020 Sep;83:104351
pubmed: 32387564
ACS Infect Dis. 2020 Sep 11;6(9):2319-2336
pubmed: 32786280
Lancet. 1998 Nov 14;352(9140):1600
pubmed: 9843113
Zoonoses Public Health. 2012 Sep;59 Suppl 2:151-7
pubmed: 22958259
Genomics. 2020 Nov;112(6):5204-5213
pubmed: 32966857
Afr J Lab Med. 2020 Aug 20;9(2):1041
pubmed: 32934915
Biomed Instrum Technol. 2013 Jul-Aug;47(4):333-8
pubmed: 23919793
PLoS Negl Trop Dis. 2017 May 15;11(5):e0005622
pubmed: 28505171
Am J Clin Pathol. 2020 Apr 15;153(5):567-570
pubmed: 32190890
J Infect Dis. 2016 Oct 15;214(suppl 3):S250-S257
pubmed: 27638946
Radiology. 2020 Aug;296(2):E32-E40
pubmed: 32101510
Curr Protoc Cytom. 2020 Jun;93(1):e77
pubmed: 32502333
PLoS Negl Trop Dis. 2017 Jun 19;11(6):e0005665
pubmed: 28628619
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Biosaf Health. 2019 Sep;1(2):56-58
pubmed: 32501443
Clin Chem. 2009 Apr;55(4):611-22
pubmed: 19246619
Euro Surveill. 2020 Dec;25(50):
pubmed: 33334398